Log in

OTCMKTS:GNBTGenerex Biotechnology Stock Price, Forecast & News

$0.59
+0.05 (+9.26 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.48
Now: $0.59
$0.60
50-Day Range
$0.43
MA: $0.53
$0.76
52-Week Range
$0.14
Now: $0.59
$1.65
Volume299,394 shs
Average Volume554,343 shs
Market Capitalization$29.77 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.59
Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices. The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.78 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNBT
CUSIPN/A
Phone416-364-2551

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.20 million
Book Value$0.09 per share

Profitability

Net Income$-9,340,000.00

Miscellaneous

Employees3
Market Cap$29.77 million
Next Earnings Date6/17/2020 (Estimated)
OptionableNot Optionable

Receive GNBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter.

Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions

How has Generex Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Generex Biotechnology's stock was trading at $0.7170 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNBT stock has decreased by 17.7% and is now trading at $0.59. View which stocks have been most impacted by Coronavirus.

When is Generex Biotechnology's next earnings date?

Generex Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, June 17th 2020. View our earnings forecast for Generex Biotechnology.

How were Generex Biotechnology's earnings last quarter?

Generex Biotechnology Co. (OTCMKTS:GNBT) announced its earnings results on Friday, March, 20th. The company reported ($0.11) earnings per share (EPS) for the quarter. The company earned $0.86 million during the quarter. View Generex Biotechnology's earnings history.

Has Generex Biotechnology been receiving favorable news coverage?

News stories about GNBT stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Generex Biotechnology earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutGenerex Biotechnology.

Who are some of Generex Biotechnology's key competitors?

What other stocks do shareholders of Generex Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generex Biotechnology investors own include SLS International (SLS), Unilife (UNISQ), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Quest Diagnostics (DGX), Marina Biotech (MRNA), VBI Vaccines (VBIV) and Vaxart (VXRT).

Who are Generex Biotechnology's key executives?

Generex Biotechnology's management team includes the following people:
  • Mr. Joseph Moscato, Chairman, Pres & CEO (Age 55)
  • Mr. Mark Corrao, CFO & Treasurer (Age 64)
  • Mr. Andrew Ro, Chief Investment Officer & Director (Age 48)
  • Mr. Richard D. Purcell, Sr. VP of Research & Drug Devel. (Age 58)
  • Mr. Terry R. Thompson, Chief Operating Officer (Age 61)

What is Generex Biotechnology's stock symbol?

Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT."

How do I buy shares of Generex Biotechnology?

Shares of GNBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Generex Biotechnology's stock price today?

One share of GNBT stock can currently be purchased for approximately $0.59.

How big of a company is Generex Biotechnology?

Generex Biotechnology has a market capitalization of $29.77 million and generates $6.20 million in revenue each year. Generex Biotechnology employs 3 workers across the globe.

What is Generex Biotechnology's official website?

The official website for Generex Biotechnology is www.generex.com.

How can I contact Generex Biotechnology?

Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The company can be reached via phone at 416-364-2551 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.